MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Arrowhead Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

13.26 0.91

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.88

Max

13.41

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1.9M

-175M

Pardavimai

2.5M

2.5M

Pelnas, tenkantis vienai akcijai

-1.39

Pelno marža

-7,008.72

Darbuotojai

609

EBITDA

4.9M

-148M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+204.35% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.7B

Ankstesnė atidarymo kaina

12.35

Ankstesnė uždarymo kaina

13.26

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Arrowhead Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-09-03 10:38; UTC

Pagrindinės rinkos jėgos

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Akcijų palyginimas

Kainos pokytis

Arrowhead Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

204.35% į viršų

12 mėnesių prognozė

Vidutinis 40.6 USD  204.35%

Aukščiausias 80 USD

Žemiausias 21 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Arrowhead Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

7

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

9.998 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.